This conference will explore new or improved therapeutic approaches for finding cures for diseases which traditionally have been difficult to treat. This includes technologies for optimizing treatments and monitoring efficacy based on insights into cell and tissue state, circuitry, behavior, function, and responsiveness in normal and disease states, biomarker detection, better methods to predict and track efficacy, and enhanced manufacturing capabilities.
Introduced by Marcus Dahllof, Associate Program Director, MIT Startup Exchange; Cliff Reid, PhD, CEO, Travera; Todd Gierahn, PhD, Cofounder, Honeycomb; Laura Indolfi, PhD, CEO & Cofounder, PanTher Therapeutics; Ulrik Nielsen, PhD, CEO & Cofounder, Torque; Jason Norris, Cofounder, Elektrofi; Patrick Stern, PhD, CEO & Founder, Sextant; Carlos Castro-Gonzalez, PhD, CEO & Cofounder, Leuko Labs; and Alec Nielsen, PhD, Cofounder, Asimov.
Looking for 8-10 startups to present their tech on April 12 at the 2022 MIT Health Science Technologies Conference: The Future of Cell & Gene Therapies.
P&G is looking for new technology-enabled solutions, services and business models that incentivize and drive lasting behavior change.
Startup Lightning Talks - 2022 MIT Health Science Technologies Conference The Future of Cell & Gene Therapies
Trond Undheim, PhD, Program Director, MIT Startup Exchange; Paula Hammond, PhD, David H. Koch Professor in Engineering and Department Head, Chemical Engineering, MIT; Laura Indolfi, PhD, CEO of PanTher Therapeutics; Peter Sandor, VP, Head of Oncology Marketing Strategy, Astellas.